Boehringer Ingelheim Corporation and Eli Lilly and Company (LLY) Release: Results of New Meta-Analysis Regarding CV Events in Linagliptin Phase 3 Trials Presented at American Diabetes Association  
6/25/2013 11:05:15 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Boehringer Ingelheim and Eli Lilly and Company today announced results from a new analysis of Phase III data demonstrating that treatment with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin is not associated with an increased risk of cardiovascular events in the treatment of Type 2 Diabetes (T2D), versus a number of comparators (placebo, glimepiride and voglibose). These findings were presented at the American Diabetes Association (ADA) 73rd Scientific Sessions®.1

Help employers find you! Check out all the jobs and post your resume.